Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Videos

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia

ARVO 2025: Association between ocular and systemic mitochondrial diseases and dementia

Articles

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and Diabetic Macular Edema (DME).

Therini Bio raises $39 million in a Series A extension financing

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

Sylentis releases topline results from phase 2a of SYL1801

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

The Role of Miotic Agents in the Management of Presbyopia

Eyecare professionals examine the emerging role of miotic agents as promising treatment options for the management of patients with presbyopia.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

Overview of Presbyopia

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Impact of Presbyopia on Mechanism of Ocular Accommodation

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

Miotic Treatment Options for Presbyopia

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Miotic Selectivity in the Management of Presbyopia

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

ICYMI: Targeting Pupil Size for Presbyopia Management

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

ICYMI: Using Miotic Agents for the Management of Presbyopia

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

Role of Aceclidine in Presbyopia Treatment

The Ophthalmology Times® Viewpoints program facilitates roundtable discussions with experts of the ophthalmic community to explore a variety of disease focused topics. Areas of discussion include diagnosis & treatment, patient journey, treatment planning, treatment options, and genetic testing.

Overview of Presbyopia

EP: 1.Overview of Presbyopia

EP: 2.Impact of Presbyopia on Mechanism of Ocular Accommodation

EP: 3.Miotic Treatment Options for Presbyopia

EP: 4.Miotic Selectivity in the Management of Presbyopia

EP: 5.ICYMI: Targeting Pupil Size for Presbyopia Management

EP: 6.ICYMI: Using Miotic Agents for the Management of Presbyopia

EP: 7.Role of Aceclidine in Presbyopia Treatment

Newsletter